To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
AAN Posters and Presentations 2025
Changes in Nonsteroidal Immunosuppressive Treatment Usage Before and After Efgartigimod Initiation in Patients With Myasthenia Gravis
January 1, 2025
Changes in Nonsteroidal Immunosuppressive Treatment Usage Before and After Efgartigimod Initiation in Patients With Myasthenia Gravis
January 1, 2025
Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
January 1, 2025
Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
January 1, 2025
COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod in Autoimmune Diseases
January 1, 2025
COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod in Autoimmune Diseases
January 1, 2025
Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
January 1, 2025
Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
January 1, 2025
First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase
January 1, 2025
First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase
January 1, 2025
Hospitalization Outcomes After Efgartigimod Initiation in Patients With Myasthenia Gravis
January 1, 2025
Hospitalization Outcomes After Efgartigimod Initiation in Patients With Myasthenia Gravis
January 1, 2025
Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
January 1, 2025
Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
January 1, 2025
Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
January 1, 2025
Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
January 1, 2025
Network Meta-Analysis of Treatment Options in Generalized Myasthenia Gravis: Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies
January 1, 2025
Network Meta-Analysis of Treatment Options in Generalized Myasthenia Gravis: Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies
January 1, 2025
Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody-Negative Generalized Myasthenia Gravis
January 1, 2025
Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody-Negative Generalized Myasthenia Gravis
January 1, 2025
Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis
January 1, 2025
Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis
January 1, 2025
Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
January 1, 2025
Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
January 1, 2025
Transition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress
January 1, 2025
Transition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress
January 1, 2025
Treatment Impact of Efgartigimod PH20 SC on I-RODS Daily Activity Assessment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational ADHERE Study
January 1, 2025
Treatment Impact of Efgartigimod PH20 SC on I-RODS Daily Activity Assessment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational ADHERE Study
January 1, 2025
Long-Term Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Interim Results From the ADHERE+ Study
January 1, 2025
Long-Term Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Interim Results From the ADHERE+ Study
January 1, 2025
AAN Posters and Presentations 2026
DESIGN OF A PHASE 4, OPEN-LABEL, SINGLE-GROUP STUDY TO EVALUATE CLINICAL OUTCOMES OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH NEW-ONSET GENERALIZED MYASTHENIA GRAVIS
January 1, 2026
DESIGN OF A PHASE 4, OPEN-LABEL, SINGLE-GROUP STUDY TO EVALUATE CLINICAL OUTCOMES OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH NEW-ONSET GENERALIZED MYASTHENIA GRAVIS
January 1, 2026
Results From the ADAPT JR Study Investigating Intravenous Efgartigiamod in Juvenile Generalized Myasthenia Gravis
January 1, 2026
Results From the ADAPT JR Study Investigating Intravenous Efgartigiamod in Juvenile Generalized Myasthenia Gravis
January 1, 2026
Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
January 1, 2026
Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
January 1, 2026
Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study
January 1, 2026
Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study
January 1, 2026
Efgartigimod is a Unique FcRn Blocker That Allows IgG Reduction Without Broad Inhibition of Immune Responses
January 1, 2026
Efgartigimod is a Unique FcRn Blocker That Allows IgG Reduction Without Broad Inhibition of Immune Responses
January 1, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis: Interim Results of ADAPT OCULUS Part A
January 1, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis: Interim Results of ADAPT OCULUS Part A
January 1, 2026
Design of a Phase 2a Study to Evaluate the Safety, Efficacy, and Tolerability of Intravenous Empasiprubart as an Add-On Therapy to Intravenous Efgartigimod in Adult Participants With Generalized Myasthenia Gravis
January 1, 2026
Design of a Phase 2a Study to Evaluate the Safety, Efficacy, and Tolerability of Intravenous Empasiprubart as an Add-On Therapy to Intravenous Efgartigimod in Adult Participants With Generalized Myasthenia Gravis
January 1, 2026
Efficacy and Safety of Efgartigimod in Anti-Acetylcholine Receptor Antibody–Negative Generalized Myasthenia Gravis: Initial Results of ADAPT SERON
January 1, 2026
Efficacy and Safety of Efgartigimod in Anti-Acetylcholine Receptor Antibody–Negative Generalized Myasthenia Gravis: Initial Results of ADAPT SERON
January 1, 2026
Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants With DOK7 Congenital Myasthenic Syndromes
January 1, 2026
Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants With DOK7 Congenital Myasthenic Syndromes
January 1, 2026
Treatment Impact of Efgartigimod PH20 SC on Grip Strength Assessment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Post Hoc Analysis of the ADHERE/ADHERE+ Study
January 1, 2026
Treatment Impact of Efgartigimod PH20 SC on Grip Strength Assessment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Post Hoc Analysis of the ADHERE/ADHERE+ Study
January 1, 2026
Serum NfL Z-score as a Biomarker of Disease Severity and Treatment History in the Largest CIDP Cohort to Date: Insights from the ADHERE Trial
January 1, 2026
Serum NfL Z-score as a Biomarker of Disease Severity and Treatment History in the Largest CIDP Cohort to Date: Insights from the ADHERE Trial
January 1, 2026
Real-World Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design
January 1, 2026
Real-World Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design
January 1, 2026
Empasiprubart Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: EMNERGIZE Phase 3 Study Design
January 1, 2026
Empasiprubart Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: EMNERGIZE Phase 3 Study Design
January 1, 2026
Empasiprubart vs Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: EMVIGORATE Phase 3 Study Design
January 1, 2026
Empasiprubart vs Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: EMVIGORATE Phase 3 Study Design
January 1, 2026
Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20
January 1, 2026
Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20
January 1, 2026
Impact of Subcutaneous Efgartigimod PH20 on Treatment-Naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the ADHERE Trial: Post Hoc Analyses
January 1, 2026
Impact of Subcutaneous Efgartigimod PH20 on Treatment-Naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the ADHERE Trial: Post Hoc Analyses
January 1, 2026
Handouts
VYVGART/VYVGART HYTRULO MG and CIDP Cross Indication Safety Neurology Congress Handout
January 1, 2026
VYVGART/VYVGART HYTRULO MG and CIDP Cross Indication Safety Neurology Congress Handout
January 1, 2026
VYVGART gMG ADAPT NXT Manuscript Clinical Data Summary Sheet
January 1, 2026
VYVGART gMG ADAPT NXT Manuscript Clinical Data Summary Sheet
January 1, 2026
Immunology Innovation Program Flyer
January 1, 2026
Immunology Innovation Program Flyer
January 1, 2026
argenx Medical Affairs: Science of Collaboration Congress Handout
January 1, 2026
argenx Medical Affairs: Science of Collaboration Congress Handout
January 1, 2026
Cross-indication Externally Sponsored Research Handout
January 1, 2026
Cross-indication Externally Sponsored Research Handout
January 1, 2026
Efgartigimod Mechanism of Action Handout
January 1, 2026
Efgartigimod Mechanism of Action Handout
January 1, 2026
ADAPT Oculus Study Design Handout
January 1, 2026
ADAPT Oculus Study Design Handout
January 1, 2026
Myositis Disease State Handout
January 1, 2026
Myositis Disease State Handout
January 1, 2026
Empasiprubart 117 Proposed Mechanism of Action handout
January 1, 2026
Empasiprubart 117 Proposed Mechanism of Action handout
January 1, 2026
MMN Disease State Handout
January 1, 2026
MMN Disease State Handout
January 1, 2026
argenx Pipeline Handout for Congresses
January 1, 2026
argenx Pipeline Handout for Congresses
January 1, 2026
SMA Adimanebart (ARGX-119) Trial Awareness Handout
January 1, 2026
SMA Adimanebart (ARGX-119) Trial Awareness Handout
January 1, 2026
Vyvgart Pregnancy Study gMG CIDP HCP card
January 1, 2026
Vyvgart Pregnancy Study gMG CIDP HCP card
January 1, 2026
VYVGART + VYVGART Hytrulo Pregnancy Registry - Referring Physician Brochure
January 1, 2026
VYVGART + VYVGART Hytrulo Pregnancy Registry - Referring Physician Brochure
January 1, 2026
ADHERE REAL Study HCP Clinical Trial Quick Card
January 1, 2026
ADHERE REAL Study HCP Clinical Trial Quick Card
January 1, 2026
Emnergize HCP Card
January 1, 2026
Emnergize HCP Card
January 1, 2026
Emvigorate HCP Card
January 1, 2026
Emvigorate HCP Card
January 1, 2026
Adapt Forward HCP Card
January 1, 2026
Adapt Forward HCP Card
January 1, 2026
CMS natural history HCP Card
January 1, 2026
CMS natural history HCP Card
January 1, 2026
CMS Phase 1b HCP Card
January 1, 2026
CMS Phase 1b HCP Card
January 1, 2026
Sparkle HCP Card
January 1, 2026
Sparkle HCP Card
January 1, 2026
Adapt Early HCP Card
January 1, 2026
Adapt Early HCP Card
January 1, 2026
Adapt Jr HCP Card
January 1, 2026
Adapt Jr HCP Card
January 1, 2026
Adapt Jr Sc HCP Card
January 1, 2026
Adapt Jr Sc HCP Card
January 1, 2026
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-NON-2400036 v6 04/2026. All Rights Reserved.